Reproducibility of food challenge to cow’s milk: a systematic review with individual participant data meta-analysis
File(s)1-s2.0-S0091674922007643-main.pdf (2.47 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Background: Cow’s milk (CM) is an increasingly common cause of severe allergic reactions, but there is uncertainty with respect to severity of reactions at low level CM exposure, as well as the reproducibility of reaction thresholds. Objective: To undertake an individual participant data (IPD) meta-analysis of studies reporting double-blind, placebo-controlled food challenges (DBPCFC) in CM, to determine the rate of anaphylaxis to low level exposures and the reproducibility of reaction thresholds. Methods: Systematic review and individual participant data (IPD) meta-analysis of studies reporting relevant data. Authors were contacted to provide additional data and/or clarifications as needed. Risk of bias was assessed using the National Institute for Clinical Excellence methodological checklists. Results: 34 studies were included, representing data from over 1000 participants. The cumulative ED01 and ED05 (cumulative doses causing objective symptoms in 1% and 5% of the at-risk allergic population) were 0.3 (95%CI 0.2-0.5) and 2.9 (95%CI 1.6-5.4) mg, respectively. At meta-analysis, 4.8% (95%CI 2.0-10.9%) and 4.8% (95%CI 0.7-27.1%) of individuals reacting to ≤5mg and ≤0.5mg of CM protein (respectively) had anaphylaxis (minimal heterogeneity,
I
2 =0%). 110 individuals subsequently underwent a repeat DBPCFC: the intra-individual variation in reaction threshold was limited to a ½-log change in 80% (95%CI 65-89%) of participants. Two individuals initially tolerated 5mg CM protein but then reacted to this dose at a subsequent challenge, although neither had anaphylaxis. Conclusions: Around 5% of CM-allergic individuals reacting to an ED01 or ED05 exposure might have anaphylaxis to that dose. This equates to 5 and 24 anaphylaxis events per 10,000 patients exposed to an ED01 or ED05 dose respectively, in the broader CM-allergic population. The vast majority of these anaphylactic reactions would be at the more mild end of the spectrum of anaphylaxis severity, responding to single dose of epinephrine.
I
2 =0%). 110 individuals subsequently underwent a repeat DBPCFC: the intra-individual variation in reaction threshold was limited to a ½-log change in 80% (95%CI 65-89%) of participants. Two individuals initially tolerated 5mg CM protein but then reacted to this dose at a subsequent challenge, although neither had anaphylaxis. Conclusions: Around 5% of CM-allergic individuals reacting to an ED01 or ED05 exposure might have anaphylaxis to that dose. This equates to 5 and 24 anaphylaxis events per 10,000 patients exposed to an ED01 or ED05 dose respectively, in the broader CM-allergic population. The vast majority of these anaphylactic reactions would be at the more mild end of the spectrum of anaphylaxis severity, responding to single dose of epinephrine.
Date Issued
2022-11-01
Date Acceptance
2022-04-29
Citation
Journal of Allergy and Clinical Immunology, 2022, 150 (5), pp.1135-1143.e8
ISSN
0091-6749
Publisher
Elsevier
Start Page
1135
End Page
1143.e8
Journal / Book Title
Journal of Allergy and Clinical Immunology
Volume
150
Issue
5
Copyright Statement
© 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
License URL
Sponsor
Medical Research Council (MRC)
Grant Number
MR/K010468/1
Subjects
Allergy
anaphylaxis
cow’s milk
eliciting dose
food challenge
precautionary allergen labeling
thresholds
Cattle
Female
Animals
Humans
Milk
Milk Hypersensitivity
Anaphylaxis
Reproducibility of Results
Allergens
Proteins
Randomized Controlled Trials as Topic
Milk
Animals
Cattle
Humans
Anaphylaxis
Milk Hypersensitivity
Proteins
Allergens
Reproducibility of Results
Female
Randomized Controlled Trials as Topic
Allergy
1107 Immunology
Publication Status
Published
Date Publish Online
2022-06-07